Fig. 5

DZD2269 synergizes with anti-PD-1 antibody or oxaliplatin in syngeneic mouse in vivo model. (A) Prostate RM-1 tumor-bearing mice were treated with 10 mg/kg anti-PD-1 antibody, with or without DZD2269 (3 mg/kg). (B) Pancreatic Pan02 tumor-bearing mice were treated with 10 mg/kg oxaliplatin with or without DZD2269 (3 mg/kg). bid: twice daily, qw: once a week. tiw: three times a week. Statistically significant difference was calculated by using two-way ANOVA (**: p < 0.01, ***: p < 0.001)